Exploration of CTNNB1 ctDNA as a putative biomarker for hepatoblastoma

Smadar Kahana-Edwin; Geoffrey McCowage; Lucy Cain; Federica Saletta; Aysen Yuksel; Nicole Graf; Jonathan Karpelowsky

doi:10.1002/pbc.28594

Exploration of CTNNB1 ctDNA as a putative biomarker for hepatoblastoma

Smadar Kahana-Edwin, Geoffrey McCowage, Lucy Cain, Federica Saletta, Aysen Yuksel, Nicole Graf, Jonathan Karpelowsky

Western Sydney University

Research output: Contribution to journal › Article › peer-review

8 Citations (Scopus)

Abstract

Driver mutations in the CTNNB1 gene (encoding β-catenin) are a hallmark of sporadic hepatoblastoma (HBL). Our results show that CTNNB1 circulating tumour DNA (ctDNA) is readily detected in patients diagnosed with localised HBL, with serial sampling along the course of therapy and follow up providing a sensitive mechanism to monitor tumour dynamics and response to treatment. This exciting potential for CTNNB1 ctDNA to serve as a biomarker for treatment response in HBL holds clinical value, and requires assessment in a larger cohort of mixed tumour stages and recurrent disease.

Original language	English
Article number	e28594
Number of pages	4
Journal	Pediatric Blood and Cancer
Volume	67
Issue number	11
DOIs	https://doi.org/10.1002/pbc.28594
Publication status	Published - 1 Nov 2020

Bibliographical note

Publisher Copyright:
© 2020 Wiley Periodicals LLC

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/pbc.28594

Cite this

@article{272d1b9ece9a44788ce93ff214805cb0,

title = "Exploration of CTNNB1 ctDNA as a putative biomarker for hepatoblastoma",

abstract = "Driver mutations in the CTNNB1 gene (encoding β-catenin) are a hallmark of sporadic hepatoblastoma (HBL). Our results show that CTNNB1 circulating tumour DNA (ctDNA) is readily detected in patients diagnosed with localised HBL, with serial sampling along the course of therapy and follow up providing a sensitive mechanism to monitor tumour dynamics and response to treatment. This exciting potential for CTNNB1 ctDNA to serve as a biomarker for treatment response in HBL holds clinical value, and requires assessment in a larger cohort of mixed tumour stages and recurrent disease.",

author = "Smadar Kahana-Edwin and Geoffrey McCowage and Lucy Cain and Federica Saletta and Aysen Yuksel and Nicole Graf and Jonathan Karpelowsky",

note = "Publisher Copyright: {\textcopyright} 2020 Wiley Periodicals LLC",

year = "2020",

month = nov,

day = "1",

doi = "10.1002/pbc.28594",

language = "English",

volume = "67",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

publisher = "John Wiley & Sons",

number = "11",

}

TY - JOUR

T1 - Exploration of CTNNB1 ctDNA as a putative biomarker for hepatoblastoma

AU - Kahana-Edwin, Smadar

AU - McCowage, Geoffrey

AU - Cain, Lucy

AU - Saletta, Federica

AU - Yuksel, Aysen

AU - Graf, Nicole

AU - Karpelowsky, Jonathan

PY - 2020/11/1

Y1 - 2020/11/1

N2 - Driver mutations in the CTNNB1 gene (encoding β-catenin) are a hallmark of sporadic hepatoblastoma (HBL). Our results show that CTNNB1 circulating tumour DNA (ctDNA) is readily detected in patients diagnosed with localised HBL, with serial sampling along the course of therapy and follow up providing a sensitive mechanism to monitor tumour dynamics and response to treatment. This exciting potential for CTNNB1 ctDNA to serve as a biomarker for treatment response in HBL holds clinical value, and requires assessment in a larger cohort of mixed tumour stages and recurrent disease.

AB - Driver mutations in the CTNNB1 gene (encoding β-catenin) are a hallmark of sporadic hepatoblastoma (HBL). Our results show that CTNNB1 circulating tumour DNA (ctDNA) is readily detected in patients diagnosed with localised HBL, with serial sampling along the course of therapy and follow up providing a sensitive mechanism to monitor tumour dynamics and response to treatment. This exciting potential for CTNNB1 ctDNA to serve as a biomarker for treatment response in HBL holds clinical value, and requires assessment in a larger cohort of mixed tumour stages and recurrent disease.

UR - https://hdl.handle.net/1959.7/uws:66526

U2 - 10.1002/pbc.28594

DO - 10.1002/pbc.28594

M3 - Article

SN - 1545-5009

VL - 67

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

IS - 11

M1 - e28594

ER -

Exploration of CTNNB1 ctDNA as a putative biomarker for hepatoblastoma

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this